Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 16 Results

Title
Intervention Indication Therapeutic Area Year Actions
AT406 (Debio 1143) for Ovarian Cancer – neoadjuvant therapy Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Xevinapant (Debio 1143; AT-406) Ovarian cancer Female Reproductive Cancer 2018 View  |  Download
Atezolizumab in addition to paclitaxel for inoperable, locally advanced or metastatic triple negative breast cancer – first-line Atezolizumab (Tecentriq; MPDL3280A) , Paclitaxel (Taxol; paclitaxel albumin) Breast cancer Breast Cancer 2019 View  |  Download
Atezolizumab in addition to paclitaxel, carboplatin and bevacizumab for epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer – first-line Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) , Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
Atezolizumab with paclitaxel and carboplatin for previously untreated advanced endometrial cancer Atezolizumab (Tecentriq; MPDL3280A) , Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) Endometrial cancer Female Reproductive Cancer 2023 View  |  Download
Capivasertib with paclitaxel for previously untreated locally advanced or metastatic triple-negative breast cancer Capivasertib , Paclitaxel (Taxol; paclitaxel albumin) Breast cancer Breast Cancer 2023 View  |  Download
Dostarlimab in addition to carboplatin and paclitaxel for recurrent or primary advanced endometrial cancer Carboplatin (Paraplatin) , Dostarlimab (TSR-042; Jemperli) , Paclitaxel (Taxol; paclitaxel albumin) Endometrial cancer Female Reproductive Cancer 2021 View  |  Download
Dostarlimab with paclitaxel and carboplatin for recurrent or primary advanced endometrial cancer Carboplatin (Paraplatin) , Dostarlimab (TSR-042; Jemperli) , Paclitaxel (Taxol; paclitaxel albumin) Endometrial cancer Female Reproductive Cancer 2023 View  |  Download
Durvalumab with carboplatin and paclitaxel with or without olaparib for newly diagnosed advanced or reccurent endometrial cancer Carboplatin (Paraplatin) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Paclitaxel (Taxol; paclitaxel albumin) Endometrial cancer Female Reproductive Cancer 2023 View  |  Download
Ipatasertib in addition to paclitaxel for locally advanced or metastatic triple-negative breast cancer Ipatasertib (GDC-0068; RG7440) , Paclitaxel (Taxol; paclitaxel albumin) Breast cancer Breast Cancer 2020 View  |  Download
Paclitaxel with Encequidar for advanced breast cancer Encequidar (HM-30181) , Paclitaxel (Taxol; paclitaxel albumin) Breast cancer Breast Cancer 2022 View  |  Download
1 2
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications